Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking daily life unlock myasthenia gravis mysteries?

NCT ID NCT07761026

Knowledge-focused Sponsor: Autoimmune Neurology Alliance Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 18, 2026 · Updated 4 times

Summary

This registry study follows adults with myasthenia gravis (MG) over time to understand how symptoms, daily functioning, and quality of life change. Participants complete surveys about their symptoms, treatments, and challenges, and may share medical records. The goal is to gather real-world insights that could improve future research and care for MG.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could reveal how myasthenia gravis evolves over time and which treatments work best, guiding better care and future research.
What could go wrong
As an observational registry, it cannot prove cause and effect, and results may be limited by self-reported data and participant dropout.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults in the United States with a healthcare provider diagnosis of myasthenia gravis will be recruited from the community. Participants may be identified through healthcare providers, patient advocacy and research organizations, existing patient communities or registries, digital and social media outreach, and direct communications. The registry is decentralized, so participants may enroll and complete study activities remotely from locations across the United States.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physician-confirmed diagnosis of myasthenia gravis (MG) * Willing and legally able to provide consent * Lives in the United States Exclusion Criteria: * Unwilling or unable to provide consent or comprehend and complete questionnaires * Cognitively impaired adults/unable to comprehend or understand the consent or overall study information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Achr myasthenia gravis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system Disease Progression Medication Adherence myasthenia gravis neuromuscular junction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Achr myasthenia gravis Achr-ab seropositive generalized myasthenia gravis MG MG - myasthenia gravis Myasthenia gravis Myasthenia gravis (MG) Myasthenia gravis associated with thymoma Myasthenia gravis crisis Myasthenia gravis exacerbations Myasthenia gravis generalised Myasthenia gravis, generalized Myasthenia gravis, musk Myasthenia gravis, ocular Myasthenia gravis, thymectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Alira Health - Virtual/Remote Site - Can Be Completed 100% Online - All US Residents Accepted

    RECRUITING

    Framingham, Massachusetts, 01702, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.